Clinical Laboratory Improvement Advisory Committee (CLIAC), 1063 [2010-100]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 5 / Friday, January 8, 2010 / Notices
opportunity announcements; (2) conduct of
Secondary Peer Review of extramural
research grants, cooperative agreements, and
contracts applications received in response to
the funding opportunity announcements as it
relates to the Center’s programmatic balance
and mission; (3) submission of secondary
review recommendations to the Center
Director of applications to be considered for
funding support; (4) review of research
portfolios; and (5) review of program
proposals. The board shall provide guidance
on the National Center of Injury Prevention
and Control’s programs and research
activities by conducting scientific peer
review of intramural research and programs
within the National Center for Injury
Prevention and Control; by ensuring
adherence to Office of Management and
Budget requirements for intramural peer
review; and by monitoring the overall
direction, focus, and success of the National
Center for Injury Prevention and Control.
Matters to be Discussed: As this meeting of
the Board of Scientific Counselors, the board
will be discussing the upcoming portfolio
topics, activities promoting the Injury
Research Agenda, and other scientific
matters.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information: Dr.
Gwendolyn Cattledge, PhD, MSEH, Deputy
Associate Director for Science and the
Designated Federal Officer for the Board of
Scientific Counselors, NCIPC, CDC, 4770
Buford Highway, NE., Mailstop F–63,
Atlanta, Georgia 30341, Telephone (770)
488–1430.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2010–22 Filed 1–7–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
pwalker on DSK8KYBLC1PROD with NOTICES
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following committee
meeting:
Times and Dates:
8:30 a.m.–5 p.m., February 9, 2010.
8:30 a.m.–3 p.m., February 10, 2010.
Place: CDC, 1600 Clifton Road, NE.,
Tom Harkin Global Communications
VerDate Nov<24>2008
16:14 Jan 07, 2010
Jkt 220001
Center, Building 19, Room 232,
Auditorium B, Atlanta, Georgia 30333.
Online Registration Required: In order
to expedite the security clearance
process at the CDC Roybal Campus
located on Clifton Road, all CLIAC
attendees are required to register for the
meeting online at least 14 days in
advance at https://wwwn.cdc.gov/cliac/
default.aspx by clicking the ‘‘Register for
a Meeting’’ link and completing all
forms according to the instructions
given. Please complete all the required
fields before submitting your
registration and submit no later than
January 26, 2010.
Status: Open to the public, limited
only by the space available. The meeting
room accommodates approximately 100
people.
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services, the
Assistant Secretary for Health, and the
Director, CDC, regarding the need for,
and the nature of, revisions to the
standards under which clinical
laboratories are regulated; the impact on
medical and laboratory practice of
proposed revisions to the standards; and
the modification of the standards to
accommodate technological advances.
Matters To Be Discussed: The agenda
will include updates from the CDC, the
Centers for Medicare & Medicaid
Services, and the Food and Drug
Administration; a report from the CLIAC
Biochemical Genetic Testing Workgroup
and discussion of the Workgroup’s
proposals related to good laboratory
practices for biochemical genetic
testing; and presentations and
discussions related to electronic health
records and electronic transmission of
laboratory information.
Agenda items are subject to change as
priorities dictate.
Providing Oral or Written Comments:
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments
whenever possible.
Oral Comments: In general, each
individual or group requesting to make
an oral presentation will be limited to
a total time of five minutes (unless
otherwise indicated). Speakers must
also submit their comments in writing
for inclusion in the meeting’s Summary
Report. To assure adequate time is
scheduled for public comments,
individuals or groups planning to make
an oral presentation should, when
possible, notify the contact person
below at least one week prior to the
meeting date.
Written Comments: For individuals or
groups unable to attend the meeting,
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
1063
CLIAC accepts written comments until
the date of the meeting (unless
otherwise stated). However, the
comments should be received at least
one week prior to the meeting date so
that the comments may be made
available to the Committee for their
consideration and public distribution.
Written comments, one hard copy with
original signature, should be provided
to the contact person below. Written
comments will be included in the
meeting’s Summary Report.
Contact Person for Additional
Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch,
Division of Laboratory Systems,
National Center for Preparedness,
Detection, and Control of Infectious
Diseases, CDC, 1600 Clifton Road, NE.,
Mailstop F–11, Atlanta, Georgia 30333;
telephone (404) 498–2741; fax (404)
498–2219; or via e-mail at
Nancy.Anderson@cdc.hhs.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for CDC and the
Agency for Toxic Substances and
Disease Registry.
Dated: December 30, 2009.
Gary J. Johnson,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2010–100 Filed 1–7–10; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\08JAN1.SGM
08JAN1
]]>Agencies
[Federal Register Volume 75, Number 5 (Friday, January 8, 2010)]
[Notices]
[Page 1063]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-100]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee (CLIAC)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) announces the following committee meeting:
Times and Dates:
8:30 a.m.-5 p.m., February 9, 2010.
8:30 a.m.-3 p.m., February 10, 2010.
Place: CDC, 1600 Clifton Road, NE., Tom Harkin Global
Communications Center, Building 19, Room 232, Auditorium B, Atlanta,
Georgia 30333.
Online Registration Required: In order to expedite the security
clearance process at the CDC Roybal Campus located on Clifton Road, all
CLIAC attendees are required to register for the meeting online at
least 14 days in advance at https://wwwn.cdc.gov/cliac/default.aspx by
clicking the ``Register for a Meeting'' link and completing all forms
according to the instructions given. Please complete all the required
fields before submitting your registration and submit no later than
January 26, 2010.
Status: Open to the public, limited only by the space available.
The meeting room accommodates approximately 100 people.
Purpose: This Committee is charged with providing scientific and
technical advice and guidance to the Secretary of Health and Human
Services, the Assistant Secretary for Health, and the Director, CDC,
regarding the need for, and the nature of, revisions to the standards
under which clinical laboratories are regulated; the impact on medical
and laboratory practice of proposed revisions to the standards; and the
modification of the standards to accommodate technological advances.
Matters To Be Discussed: The agenda will include updates from the
CDC, the Centers for Medicare & Medicaid Services, and the Food and
Drug Administration; a report from the CLIAC Biochemical Genetic
Testing Workgroup and discussion of the Workgroup's proposals related
to good laboratory practices for biochemical genetic testing; and
presentations and discussions related to electronic health records and
electronic transmission of laboratory information.
Agenda items are subject to change as priorities dictate.
Providing Oral or Written Comments: It is the policy of CLIAC to
accept written public comments and provide a brief period for oral
public comments whenever possible.
Oral Comments: In general, each individual or group requesting to
make an oral presentation will be limited to a total time of five
minutes (unless otherwise indicated). Speakers must also submit their
comments in writing for inclusion in the meeting's Summary Report. To
assure adequate time is scheduled for public comments, individuals or
groups planning to make an oral presentation should, when possible,
notify the contact person below at least one week prior to the meeting
date.
Written Comments: For individuals or groups unable to attend the
meeting, CLIAC accepts written comments until the date of the meeting
(unless otherwise stated). However, the comments should be received at
least one week prior to the meeting date so that the comments may be
made available to the Committee for their consideration and public
distribution. Written comments, one hard copy with original signature,
should be provided to the contact person below. Written comments will
be included in the meeting's Summary Report.
Contact Person for Additional Information: Nancy Anderson, Chief,
Laboratory Practice Standards Branch, Division of Laboratory Systems,
National Center for Preparedness, Detection, and Control of Infectious
Diseases, CDC, 1600 Clifton Road, NE., Mailstop F-11, Atlanta, Georgia
30333; telephone (404) 498-2741; fax (404) 498-2219; or via e-mail at
Nancy.Anderson@cdc.hhs.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for CDC and the Agency for Toxic Substances and Disease Registry.
Dated: December 30, 2009.
Gary J. Johnson,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2010-100 Filed 1-7-10; 8:45 am]
BILLING CODE 4163-18-P
